tert-Butyl-[2-fluoro-4-((S)-1-oxiranylmethoxy)-phenoxy]-diphenyl-silane | 392621-01-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: tert-Butyl-[2-fluoro-4-((S)-1-oxiranylmethoxy)-phenoxy]-diphenyl-silane
• 英文别名: t-Butyl{2-fluoro-4-[(2s)oxiranylmethoxy]phenoxy}diphenylsilane；tert-butyl-[2-fluoro-4-[[(2S)-oxiran-2-yl]methoxy]phenoxy]-diphenylsilane
• CAS: 392621-01-1
• 化学式: C₂₅H₂₇FO₃Si
• 分子量: 422.571
• InChiKey: LCVAQKYEMWTTCO-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.54
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  31
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-Butyl-[2-fluoro-4-((S)-1-oxiranylmethoxy)-phenoxy]-diphenyl-silane 在 四丁基氟化铵 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-(2,5-Difluoro-benzyl)-3-[4-(4-{[(2S)-3-(3-fluoro-4-hydroxy-phenoxy)-2-hydroxy-propylamino]-methyl}-piperidine-1-sulfonyl)-phenyl]-urea
  参考文献：
  名称：

  Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: aryloxypropanolaminomethylpiperidines

  摘要：

  The synthesis and SAR of a series of human beta(3) adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified such as 26 that was in vitro active in CHO cells expressing human beta(3)-AR (EC50 = 49 nNl, IA = 1.1), and in vivo active in a transgenic mouse model. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00607-8
• 作为产物：
  描述：

  (R)-缩水甘油 、 4-{[tert-Butyl(diphenyl)silyl]oxy}-3-fluorophenol 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 tert-Butyl-[2-fluoro-4-((S)-1-oxiranylmethoxy)-phenoxy]-diphenyl-silane
  参考文献：
  名称：

  Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: aryloxypropanolaminomethylpiperidines

  摘要：

  The synthesis and SAR of a series of human beta(3) adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified such as 26 that was in vitro active in CHO cells expressing human beta(3)-AR (EC50 = 49 nNl, IA = 1.1), and in vivo active in a transgenic mouse model. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00607-8

文献信息

• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供了具有公式I结构的化合物，其中1U、V、W、X和Y的定义如前所述，或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖耐受性有关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼压增高和频繁排尿；并且在治疗或抑制2型糖尿病方面特别有用。
• Heterocyclic &bgr;-3 adrenergic receptor agonists
  申请人：Wyeth

  公开号：US06451814B1

  公开（公告）日：2002-09-17

  This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供I式化合物，其中U、V、W、X和Y的结构如前所定义，或其药学上可接受的盐，其用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐症相关），动脉粥样硬化，胃肠道疾病，神经炎症，青光眼，眼压增高和频繁排尿；并且在治疗或抑制II型糖尿病方面特别有用。
• Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine &bgr;-3 adrenergic receptor agonists
  申请人：Wyeth

  公开号：US06506901B2

  公开（公告）日：2003-01-14

  This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供具有式I的化合物，其结构中A、B、Z、R和R1如前所定义，或其药学上可接受的盐，这些化合物在治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖耐受性不良有关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼压增高和频繁排尿方面非常有用；并且在治疗或抑制II型糖尿病方面特别有用。
• Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: aryloxypropanolaminomethylpiperidines
  作者：Robert J. Steffan、Mark A. Ashwell、William R. Solvibile、Edward Matelan、Elwood Largis、Stella Han、Jeffery Tillet、Ruth Mulvey

  DOI：10.1016/s0960-894x(02)00607-8

  日期：2002.10

  The synthesis and SAR of a series of human beta(3) adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified such as 26 that was in vitro active in CHO cells expressing human beta(3)-AR (EC50 = 49 nNl, IA = 1.1), and in vivo active in a transgenic mouse model. (C) 2002 Elsevier Science Ltd. All rights reserved.